\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationOnline
ProgrammesAre you working on a cybersecurity project, service or product and do you need help on how to fund it? Collaborative research and innovation projects funded through Horizon Europe and the Digital Europe Programme might be the right tool for you.
This workshop is dedicated to providing detailed information about the upcoming Digital Europe and Horizon Europe calls. You will be able to present your organisation, pitch your ideas and your existing consortia, and ask questions. It's also a great opportunity to connect with potential partners in the Benelux region.
The webinar is hosted by the National Coordination Centres for Cybersecurity (NCCs) in the Benelux: NEXIS (NCC-NL), Centre for Cybersecurity Belgium (NCC-BE), and Luxembourg House of Security (NCC-LU).
For the programme and more information about this workshop and subscription, please visit the official event page via this link.
Also good to know: Calls Opening - Countdown
On 27 June, the 2024 Calls of Cluster 3 - Civil Security for Society will open. Submissions will be accepted until 20 November. On 4 July, the next Digital Europe calls will open, deadline to submit proposals is 21 January 2025. Stay tuned and don't hesitate to contact us in case of questions.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
